FINEARTS-HF met its primary endpoint, 1 achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits 2 KERENDIA is the first non-steroidal, selective mineralocorticoid receptor antagonist (MRA) to meet a primary cardiovascular endpoint in a Phase III study investigating patients with HF with mildly reduced or preserved ejection fraction (LVEF > 40%) 1 KERENDIA already has established cardiovascular benefit (reduction in hospitalization for HF, CV death and non-fatal MI) in adults with chronic kidney disease (CKD) in type 2 diabetes (T2D) 3 , and this new topline data provides positive results in a different patient population not limited to CKD in T2D— patients diagnosed with HF (LVEF > 40) 1 The clinical data from FINEARTS-HF will be presented at the European Society of Cardiology (ESC) Congress 2024 Bayer plans to discuss the data and